FRA:5HZ1 (China)
Â
Class H
€
4.16
+0.20 (+5.05%)
Jul 14
Business Description
Hangzhou Tigermed Consulting Co Ltd
ISIN : CNE1000040M1
Share Class Description:
FRA:5HZ1: Class HTotal Employee Number:
11,130Compare
Compare
Traded in other countries / regions
300347.China03347.Hong Kong5HZ1.GermanyHNGZY.USA IPO Date
2021-06-16Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 1.56 | |||||
Interest Coverage | 9.26 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.04 | |||||
Beneish M-Score | -2.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.8 | |||||
3-Year EBITDA Growth Rate | -21.1 | |||||
3-Year EPS without NRI Growth Rate | -38.2 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 2.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.38 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.19 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.79 | |||||
9-Day RSI | 67.67 | |||||
14-Day RSI | 63.82 | |||||
3-1 Month Momentum % | -23.71 | |||||
6-1 Month Momentum % | -37.89 | |||||
12-1 Month Momentum % | -31.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.3 | |||||
Quick Ratio | 2.28 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 3.12 | |||||
Days Sales Outstanding | 68.52 | |||||
Days Payable | 23.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.39 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | -15.7 | |||||
Forward Dividend Yield % | 0.39 | |||||
5-Year Yield-on-Cost % | 0.58 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 4.02 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 26.64 | |||||
Operating Margin % | 9.61 | |||||
Net Margin % | 10.91 | |||||
EBITDA Margin % | 15.65 | |||||
FCF Margin % | 14.45 | |||||
OCF Margin % | 17.51 | |||||
ROE % | 3.71 | |||||
ROA % | 2.69 | |||||
ROIC % | 2.12 | |||||
3-Year ROIIC % | -17.18 | |||||
ROC (Joel Greenblatt) % | 66.13 | |||||
ROCE % | 4.34 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 57.03 | |||||
Forward PE Ratio | 22.75 | |||||
PE Ratio without NRI | 84.8 | |||||
Shiller PE Ratio | 35.55 | |||||
Price-to-Owner-Earnings | 87.82 | |||||
PS Ratio | 6.17 | |||||
PB Ratio | 2.14 | |||||
Price-to-Tangible-Book | 2.6 | |||||
Price-to-Free-Cash-Flow | 42.72 | |||||
Price-to-Operating-Cash-Flow | 35.26 | |||||
EV-to-EBIT | 38.98 | |||||
EV-to-Forward-EBIT | 16.72 | |||||
EV-to-EBITDA | 38.98 | |||||
EV-to-Revenue | 6.1 | |||||
EV-to-Forward-Revenue | 6.04 | |||||
EV-to-FCF | 42.23 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 1.52 | |||||
Price-to-Median-PS-Value | 0.53 | |||||
Price-to-Graham-Number | 3.13 | |||||
Earnings Yield (Greenblatt) % | 2.57 | |||||
FCF Yield % | 2.4 | |||||
Forward Rate of Return (Yacktman) % | -30.19 |
Hangzhou Tigermed Consulting Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hangzhou Tigermed Consulting Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| HKD 0.144680 Cash Dividend | 2026-06-18 | 3.34 (+0.00%) | ||
| HKD 0.324500 Cash Dividend | 2025-06-12 | 4.40 (-1.79%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Tigermed Announces 2025 Annual Results | 2026-03-30 | ||
| Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30 | 2025-11-06 | ||
| Tigermed Receives MSCI ESG AAA Rating | 2025-08-18 | ||
| Tigermed Completes Acquisition of Japanese CRO Micron | 2025-07-29 | ||
| Tigermed Reports Full Year 2024 Results | 2025-03-27 | ||
| Tigermed Reports 2024 Interim Results | 2024-08-28 | ||
| Tigermed Reports Full Year 2023 Results | 2024-03-28 | ||
| Tigermed Reports 2023 Interim Results | 2023-08-25 | ||
| Tigermed Officially Opens International Headquarters in Hong Kong | 2023-08-17 | ||
| Tigermed Officially Opens International Headquarters in Hong Kong | 2023-08-16 |
Articles on Hangzhou Tigermed Consulting Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers